MESO
Mesoblast limited.

5,290
Mkt Cap
$1.84B
Volume
170,848.00
52W High
$22.00
52W Low
$9.61
PE Ratio
-16.93
MESO Fundamentals
Price
$14.32
Prev Close
$14.85
Open
$15.07
50D MA
$16.46
Beta
1.42
Avg. Volume
240,375.78
EPS (Annual)
-$0.8443
P/B
3.07
Rev/Employee
$211,960.04
Loading...
Loading...
News
all
press releases
Mesoblast Appoints James M O'Brien New CFO
(RTTNews) - Mesoblast Ltd. (MESO, MSB.AX), an Australian regenerative medicine company, Monday announced the appointment of James M O'Brien as its US-based Chief Financial Officer or CFO. The company...
Nasdaq News: Markets·4d ago
News Placeholder
More News
News Placeholder
Bears are Losing Control Over Mesoblast Limited (MESO), Here's Why It's a 'Buy' Now
After losing some value lately, a hammer chart pattern has been formed for Mesoblast Limited (MESO), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Zacks·10d ago
News Placeholder
All You Need to Know About Mesoblast Limited (MESO) Rating Upgrade to Buy
Mesoblast Limited (MESO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·22d ago
News Placeholder
Mesoblast Limited (MESO) Is Up 40.59% in One Week: What You Should Know
Does Mesoblast Limited (MESO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks·4mo ago
News Placeholder
Mesoblast Gives Positive Update About Potential FDA Application For Heart Failure Therapy: Retail Sees ‘Inflection Point’
The company is also looking forward to a meeting with the FDA in early July to discuss a trial of Ryoncil in adults with steroid-refractory acute graft-versus-host disease.
Stocktwits·5mo ago
News Placeholder
Mesoblast Nears Major FDA Approvals and Advances Trials
Mesoblast Limited (AU:MSB) has released an update. Mesoblast Limited is poised for a major breakthrough with the potential FDA approval of their pr...
TipRanks Financial Blog·1y ago
News Placeholder
Mesoblast Seeks FDA Approval for Pediatric SR-aGVHD Therapy
Mesoblast Limited (AU:MSB) has released an update. Mesoblast Limited, a global leader in cellular medicines for inflammatory diseases, announced th...
TipRanks Financial Blog·1y ago
News Placeholder
Mesoblast (NASDAQ:MESO) Sees Strong Trading Volume
Mesoblast Limited (NASDAQ:MESO - Get Free Report) shares saw unusually-high trading volume on Monday . Approximately 5,883,669 shares were traded during mid-day trading, an increase of 210% from the...
Ticker Report·2y ago
News Placeholder
Mesoblast (NASDAQ:MESO) Trading Up 6.6%
Mesoblast Limited (NASDAQ:MESO - Get Free Report)'s share price was up 6.6% on Tuesday . The company traded as high as $6.48 and last traded at $6.48. Approximately 1,516,520 shares changed hands...
Ticker Report·2y ago
News Placeholder
Mesoblast (NASDAQ:MESO) Shares Gap Up to $3.49
Mesoblast Limited (NASDAQ:MESO - Get Free Report)'s share price gapped up prior to trading on Thursday . The stock had previously closed at $3.49, but opened at $4.46. Mesoblast shares last traded at...
Ticker Report·2y ago

Latest MESO News

View

Advertisement|Remove ads.

Advertisement|Remove ads.